Evidence map›Paper›PMID 41295394›Full record

ArticleMarine drugs2025

Structural Comparison and Therapeutic Effects on Ulcerative Colitis of Fucoidan and Its Derivative from

Yanlei Yu, Xiaoshu Jin, Yunjie Zhao, Ningning Wang, Yi Hua, Youmin Ying, Bin Wei, Hong Wang

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Marine drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yanlei YuCollege of Pharmaceutical Science & Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, China.
Xiaoshu JinCollege of Pharmaceutical Science & Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, China.
Yunjie ZhaoCollege of Pharmaceutical Science & Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, China.
Ningning WangCollege of Pharmaceutical Science & Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, China.
Yi HuaCollege of Pharmaceutical Science & Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, China.
Youmin YingCollege of Pharmaceutical Science & Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, China.
Bin WeiCollege of Pharmaceutical Science & Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, China.ORCID 0000-0002-2862-2907
Hong WangCollege of Pharmaceutical Science & Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou 310014, China.ORCID 0000-0003-0058-060X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that can lead to intestinal complications and systemic risks, significantly increasing the likelihood of colorectal cancer in individuals with long-term illness. Fucoidan has shown potential in alleviating UC; however, the structure-activity relationship remains challenging. The present study aims to compare fucoidan (CF) and its degraded derivatives (DF) in the prevention and treatment of UC. Structural analysis demonstrated that CF and DF possess similar monosaccharide compositions and sulfation content; however, they differ significantly in molecular weight, with CF measuring 582 kDa and DF 2.3 kDa. Additionally, DF display a lower degree of branching compared to CF. Results from the mouse model demonstrated that both CF and DF can effectively alleviate clinical symptoms of UC; however, the underlying mechanisms of action are likely to differ. Both CF and DF produced comparable improvements in the disease activity index. CF demonstrated superior efficacy in alleviating weight loss and maintaining colon length, whereas DF showed greater benefits in protecting the colonic mucosa and reducing inflammatory infiltration. The gut microbiota analysis indicated that DF was more effective in restoring microbial diversity in UC mice. Both CF and DF were capable of modulating microbial imbalances at the phylum and genus levels, although the specific taxa exhibited differences.

Indexed as

Colitis, UlcerativePhaeophyceaePolysaccharidesAnimalsColonDisease Models, AnimalEdible SeaweedsGastrointestinal MicrobiomeIntestinal MucosaLaminariaMaleMiceMice, Inbred C57BLMolecular WeightStructure-Activity RelationshipfucoidanPolysaccharidesfucoidangut microbiotastructural comparisonulcerative colitis

Identifiers

PMID41295394
PMCPMC12654075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.